Key Data Updates From IASLC 2023 World Conference on Lung Cancer
The oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by expert Stephen Liu, MD, to review key data from the IALSC 2023 World Conference on Lung Cancer and consider their impact on clinical practice.
EP. 1: Data From FLAURA2: Osimertinib With or Without Chemotherapy in Metastatic NSCLC
Expert Stephen Liu, MD, joins the Oncology Brothers to share insight into updated data from the FLAURA2 trial of osimertinib with or without chemotherapy in patients with metastatic non–small cell lung cancer.
EP. 2: CHRYSALIS-2: Amivantamab + Lazertinib in Non–Small Cell Lung Cancer
Key opinion leaders review data from the CHRYSALIS-2 trial and consider the optimal utilization of amivantamab and lazertinib in combination in the setting of non–small cell lung cancer management.
EP. 3: Evaluating the Role of Surgery in Mesothelioma: The MARS2 Trial
Switching their focus to the mesothelioma treatment space, Stephen Liu, MD, and Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, consider the role of surgical resection following data from MARS2.
EP. 4: EVOKE-02: Sacituzumab Govitecan + Pembrolizumab in Non–Small Cell Lung Cancer
Shared insight into data from the EVOKE-02 study of sacituzumab govitecan in combination with pembrolizumab in patients with non–small cell lung cancer stratified by PD-L1 expression.
EP. 5: Closing Thoughts on Data Updates From IASLC 2023 World Conference on Lung Cancer
Following their review of data from the IASLC 2023 World Conference on Lung Cancer with expert Stephen Liu, MD, Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, highlight key takeaways and future directions in care.
